Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 22,255 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Cystic Fibrosis
Interventions: Tezacaftor/Ivacaftor, Ivacaftor, Tezacaftor/Ivacaftor matching placebo, Ivacaftor matching placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 4 more

Conditions: Psilocybin
Interventions: Psilocybin, Midazolam, Saline; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Intimate Partner Violence
Interventions: Couple CARE for Parents; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes, De Novo Lipogenesis
Interventions: Oral Glucose Tolerance Test; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 22 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Brain Injuries
Interventions: Problem-solving, education based telephone counseling, No Intervention; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 16 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Smoking
Interventions: guanfacine, placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Smoking, Nicotine Dependence, Mental Disorders
Interventions: Cognitive / Motivational Individual Sessions, Attention Control Individual Sessions, Nicotine Patch, Group Curriculum; Behavioral · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Macular Degeneration, Central Visual Impairment
Interventions: 'Scotoma awareness' Training, Control Training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Obesity
Interventions: Physical Activity; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 60 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Greenville, North Carolina • Pittsburgh, Pennsylvania

Conditions: Mild Cognitive Impairment, Hypertension
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: JCARH125, JCARH125 + anakinra; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more

Conditions: Duchenne Muscular Dystrophy
Interventions: SGT-003, Placebo; Drug
Lead sponsor: Solid Biosciences Inc.; Industry
Eligibility: 7 Years to 11 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 3
States / cities: Little Rock, Arkansas • Flower Mound, Texas • Norfolk, Virginia

Conditions: Pain, Postoperative
Interventions: Ibuprofen 600 mg, Local anesthetic Group 1, Placebo oral capsule, Local anesthetic Control; Drug
Lead sponsor: Satheesh Elangovan; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 34
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
Interventions: Pimicotinib(ABSK021), Placebo; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 8
States / cities: Beverly Hills, California • Durham, California • Detroit, Michigan + 5 more

Conditions: Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions: G-Pen, Lilly Glucagon; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more

Conditions: Pain
Interventions: placebo, valdecoxib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 68
States / cities: Birmingham, Alabama • Northport, Alabama • Glendale, Arizona + 46 more

Conditions: Hypertension, Pre Hypertension, Obesity
Interventions: Clinical Decision Support (CDS); Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 10 Years to 17 Years
Enrollment: 31,579 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity and Overweight
Interventions: Commercial weight management program; Behavioral
Lead sponsor: WW International Inc; Industry
Eligibility: 18 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Papillomavirus Infections
Interventions: Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more

Conditions: Diabetes Mellitus
Interventions: PPM-204; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 11
States / cities: Artesia, California • Los Angeles, California • Chipley, Florida + 8 more

Conditions: Healthy Volunteers
Interventions: TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: ICD, Anxiety, Patient Engagement
Interventions: Dance4Healing Telehealth Live Zoom Sessions, Dance Buddy; Behavioral
Lead sponsor: Sanjiv Narayan, MD, PhD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Tobacco Product Beliefs and Use
Interventions: Modified Risk Claim Type - None, Product Brand - General Snus, Product Brand - Copenhagen, Modified Risk Claim Type - Multiple Diseases, Modified Risk Claim Type - Lung Cancer; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years and older
Enrollment: 1,257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Search by objective public record fields.

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

The RECAP2 Study: Midazolam and Psilocybin

Dyadic, Skills-Based Primary Prevention for Partner Violence in Perinatal Parents

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

Telephone Intervention for Caregivers of Persons With Traumatic Brain Injury

Modeling Stress-precipitated Smoking Behavior for Medication Development

Helping Those With Mental Illness Quit Smoking

Scotoma Perimetry Oculomotor Training

Physical Activity Following Surgery Induced Weight Loss

Hypertension, Brain Clearance, and Markers of Neurodegeneration

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Pre-Emptive Analgesia in Dental Implant Surgery

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction

Electronic Health Record-Based Clinical Decision Support to Improve Blood Pressure Management in Adolescents

A Randomized Controlled Trial Comparing the Efficacy of Commercial Weight Management Programs

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Dance4Healing: Explore the Benefits of Tele-Dance in Individuals with an Implantable Cardioverter-defibrillator (ICD)

Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes